Structure CEO warns compounded weight-loss drugs could threaten new obesity treatments as the company prepares to bring its ...
Structure Therapeutics' (GPCR) subsidiary Gasherbrum Bio signed a patent license agreement with Genentech, granting Genentech ...
Zacks Investment Research on MSN
LLY stock falls after FDA reportedly delays obesity drug ruling
Eli Lilly and Company’s LLY stock declined 3.8% on Thursday after the FDA reportedly delayed its decision on LLY’s ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback